Products
Luvagrobart Biosimilar Monoclonal Antibody (NGF) for Research
Cat No.: GMP-Bios-INN-1275
Anti-NGF therapeutic antibody (Pre-made Luvagrobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Luvagrobart (development code AK115) is a monoclonal antibody targeting nerve growth factor (NGF). It is developed by Akeso Biopharma for cancer pain. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1275-1mg | 1mg | 3090 |
| GMP-Bios-INN-1275-10mg | 10mg | |
| GMP-Bios-INN-1275-100mg | 100mg | |
| GMP-Bios-INN-1275-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Luvagrobart biosimilar, Whole mAb, Anti-NGF Antibody: Anti-NGF/beta NGF/Beta-nerve growth factor/Beta-NGF therapeutic antibody |
| INN Name | Luvagrobart |
| Target | NGF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4edw:HL |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Akeso Biopharma |
| Conditions Approved | na |
| Conditions Active | Cancer pain;Pain |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
